| DIRECT COMPETITOR COMPARISON | |
| UGNE.OB | LLY | EMIS.OB | NVS | Industry | | Market Cap: | 68.56M | 41.46B | 37.86M | 124.55B | 169.04M | | Employees: | 103 | 40,500 | 20 | 99,000 | 94 | | Qtrly Rev Growth (yoy): | -46.30% | 6.80% | N/A | 2.40% | 20.50% | | Revenue (ttm): | 15.07M | 21.11B | 5.00K | 42.31B | 46.74M | | Gross Margin (ttm): | 78.55% | 82.33% | 100.00% | 72.61% | 56.06% | | EBITDA (ttm): | -10.52M | 7.74B | -15.43M | 11.24B | -7.12M | | Oper Margins (ttm): | -74.58% | 30.97% | -322,640.00% | 21.50% | 2.25% | | Net Income (ttm): | -14.91M | -216.00M | -21.34M | 7.59B | N/A | | EPS (ttm): | -0.165 | -0.197 | -0.673 | 3.34 | -0.17 | | P/E (ttm): | N/A | N/A | N/A | 16.42 | 17.72 | | PEG (5 yr expected): | N/A | 6.28 | N/A | 2.9 | 1.06 | | P/S (ttm): | 4.85 | 1.96 | 7488.46 | 2.93 | 4.48 |
|
| LLY = Eli Lilly & Co. | | EMIS.OB = Emisphere Technologies, Inc. | | NVS = Novartis AG | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.42 | 0.12% | 58.12B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.24 | 0.15% | 15.11B | 17.48 | | Genzyme Corp. | GENZ | 48.50 | 0.62% | 12.87B | 27.65 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.00 | -0.02% | 38.70B | 16.63 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.17 | 0.68% | 9.30B | 1064.69 | | Teva Pharmaceutical Industries Limited | TEVA | 55.94 | -0.07% | 49.28B | 51.18 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.91 | 0.28% | 4.24B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.14 | -0.82% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.74 | 0.00% | 5.73B | 114.97 | | Pfizer Inc. | PFE | 18.60 | 0.11% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.70 | 0.20% | 178.51B | 14.13 | | GlaxoSmithKline plc | GSK | 42.29 | 0.48% | 107.21B | 13.87 | | Sanofi-Aventis | SNY | 39.87 | 0.43% | 104.11B | N/A | | Novartis AG | NVS | 54.84 | 0.44% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.20 | 0.93% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 0.89% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.15 | 0.11% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.76 | 0.23% | 51.03B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LLY | | [$$] Dwindling Options at Take-Two
Thu, Dec 24 -
at Barrons.com | | • | NVS | | Many Reasons to Launch a Global Generic Drug ETF
Thu, Dec 24 -
at Seeking Alpha | | • | NVS | | Obama's Health-Care Reform "Quite Positive" for Big Pharma, Managed Care Stocks
Thu, Dec 24 -
TechTicker | | • | NVS | | Novartis to pay $120M for Corthera
Thu, Dec 24 -
at bizjournals.com | | • | NVS | | Art Cashin: Class Warfare a Threat to US Recovery
Thu, Dec 24 -
at CNBC | | • | LLY | | Another Reason to Worry About Pfizer
Thu, Dec 24 -
at Motley Fool | | • | LLY | | Pfizer Expands Chinese Presence
Thu, Dec 24 -
Zacks.com | | • | LLY | | Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
Thu, Dec 24 -
at Seeking Alpha | | • | LLY | | Pharma Spreads Holiday Cheer in Bevy of Biotech Deals
Thu, Dec 24 -
at Seeking Alpha | | • | NVS | | Sanofi Pulls the Plug on Two Drugs: Biotech's Latest Mishaps
Thu, Dec 24 -
at Seeking Alpha | | • | LLY | | UPDATE - Amylin shares drop after FDA requests new studies
Wed, Dec 23 -
at Reuters | | • | NVS | | [$$] Novartis Bets on Heart Drug
Wed, Dec 23 -
at The Wall Street Journal Online | | • | LLY | | Eli Lilly, Kowa Partner to Market Cholesterol Drug Livalor in U.S.
Wed, Dec 23 -
at Fox Business | | • | NVS | | Synta Pharma starts midstage study of cancer drug
Wed, Dec 23 -
AP | | • | NVS | | TradingMarkets 7 Stocks You Need to Know for Thursday
Wed, Dec 23 -
TradingMarkets.com | | • | LLY | | Novartis Partnership And International Sales Position Cubist Pharmaceuticals As A Good Investment, According To Former Vice President Of Morgan Stanley
Wed, Dec 23 -
Wall Street Transcript | | • | NVS | | Senior Portfolio Manager Picks Cubist Pharmaceuticals (CBST): Strong Product Offerings And Sky High Sales Make This Stock A Top Pick
Wed, Dec 23 -
Wall Street Transcript | | • | EMIS.OB | | Meta-Analysis of Independent Research Supports Potential for Oral Salmon Calcitonin Using Emisphere's Eligen® Technology as Therapeutic Option for Persistent Musculoskeletal Pain
Mon, Dec 21 -
Business Wire | | • | EMIS.OB | | Emisphere Technologies Reports DMC Recommendation to Proceed with Phase 3 Clinical Trials with Oral Calcitonin for Osteoporosis and Osteoarthritis
Thu, Dec 10 -
Business Wire | | • | EMIS.OB | | EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mon, Nov 30 -
EDGAR Online | | • | EMIS.OB | | Emisphere Technologies Announces Extension of Maturity Date for Novartis Convertible Promissory Note
Mon, Nov 30 -
Business Wire | | • | EMIS.OB | | Emisphere Technologies to Present at the New York Society of Security Analysts' 13th Annual Biotech & Specialty Pharma Investment Conference
Tue, Nov 24 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.51% Nasdaq 
0.05 (6.25%) 
Competitors
